LEXX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LEXX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Lexaria Bioscience's adjusted earnings per share data for the three months ended in Aug. 2024 was $-0.150. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.45 for the trailing ten years ended in Aug. 2024.
During the past 3 years, the average E10 Growth Rate was -1.40% per year. During the past 5 years, the average E10 Growth Rate was -1.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.
During the past 13 years, the highest 3-Year average E10 Growth Rate of Lexaria Bioscience was 18.10% per year. The lowest was -4.10% per year. And the median was -0.80% per year.
As of today (2024-12-12), Lexaria Bioscience's current stock price is $2.26. Lexaria Bioscience's E10 for the quarter that ended in Aug. 2024 was $-1.45. Lexaria Bioscience's Shiller PE Ratio of today is .
The historical data trend for Lexaria Bioscience's E10 can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexaria Bioscience Annual Data | |||||||||||||||||||||
Trend | Aug15 | Aug16 | Aug17 | Aug18 | Aug19 | Aug20 | Aug21 | Aug22 | Aug23 | Aug24 | |||||||||||
E10 | Get a 7-Day Free Trial | -1.41 | -1.39 | -1.52 | -1.59 | -1.45 |
Lexaria Bioscience Quarterly Data | ||||||||||||||||||||
Nov19 | Feb20 | May20 | Aug20 | Nov20 | Feb21 | May21 | Aug21 | Nov21 | Feb22 | May22 | Aug22 | Nov22 | Feb23 | May23 | Aug23 | Nov23 | Feb24 | May24 | Aug24 | |
E10 | Get a 7-Day Free Trial | -1.59 | -1.57 | -1.54 | -1.51 | -1.45 |
For the Biotechnology subindustry, Lexaria Bioscience's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Lexaria Bioscience's Shiller PE Ratio falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.
What is E10? How do we calculate E10?
E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.
We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Lexaria Bioscience's adjusted earnings per share data for the three months ended in Aug. 2024 was:
Adj_EPS | = | Earnings per Share (Diluted) | / | CPI of Aug. 2024 (Change) | * | Current CPI (Aug. 2024) |
= | -0.15 | / | 127.8378 | * | 127.8378 | |
= | -0.150 |
Current CPI (Aug. 2024) = 127.8378.
Lexaria Bioscience Quarterly Data
per share eps | CPI | Adj_EPS | |
201411 | -0.273 | 99.078 | -0.352 |
201502 | -0.273 | 99.078 | -0.352 |
201505 | -0.273 | 100.263 | -0.348 |
201508 | -0.109 | 100.579 | -0.139 |
201511 | -0.300 | 100.421 | -0.382 |
201602 | -0.300 | 100.421 | -0.382 |
201605 | -0.300 | 101.765 | -0.377 |
201608 | -0.300 | 101.686 | -0.377 |
201611 | -0.300 | 101.607 | -0.377 |
201702 | -0.300 | 102.476 | -0.374 |
201705 | -0.300 | 103.108 | -0.372 |
201708 | -0.300 | 103.108 | -0.372 |
201711 | -0.300 | 103.740 | -0.370 |
201802 | -0.600 | 104.688 | -0.733 |
201805 | -1.500 | 105.399 | -1.819 |
201808 | -0.300 | 106.031 | -0.362 |
201811 | -0.300 | 105.478 | -0.364 |
201902 | -0.300 | 106.268 | -0.361 |
201905 | -0.300 | 107.927 | -0.355 |
201908 | -0.300 | 108.085 | -0.355 |
201911 | -0.330 | 107.769 | -0.391 |
202002 | -0.380 | 108.559 | -0.447 |
202005 | -0.500 | 107.532 | -0.594 |
202008 | -0.240 | 108.243 | -0.283 |
202011 | -0.240 | 108.796 | -0.282 |
202102 | 0.090 | 109.745 | 0.105 |
202105 | -0.500 | 111.404 | -0.574 |
202108 | -0.240 | 112.668 | -0.272 |
202111 | -0.350 | 113.932 | -0.393 |
202202 | -0.250 | 115.986 | -0.276 |
202205 | -0.410 | 120.016 | -0.437 |
202208 | -0.240 | 120.569 | -0.254 |
202211 | -0.300 | 121.675 | -0.315 |
202302 | -0.220 | 122.070 | -0.230 |
202305 | -0.370 | 124.045 | -0.381 |
202308 | -0.120 | 125.389 | -0.122 |
202311 | -0.130 | 125.468 | -0.132 |
202402 | -0.060 | 125.468 | -0.061 |
202405 | -0.130 | 127.601 | -0.130 |
202408 | -0.150 | 127.838 | -0.150 |
Add all the adjusted EPS together and divide 10 will get our e10.
Lexaria Bioscience (NAS:LEXX) E10 Explanation
If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.
For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.
The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Be Aware
Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.
Thank you for viewing the detailed overview of Lexaria Bioscience's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.
Catherine C. Turkel | director | 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612 |
Vanessa Carle | officer: Secretary | 100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7 |
Gregory Downey | officer: Chief Financial Officer | 100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7 |
Christopher Bunka | director, 10 percent owner, officer: CEO | 1924 BIRKDALE AVE, KELOWNA A1 V1P1R7 |
Reese Albert L Jr | director | |
Brian W. Quigley | director | 100 740 MCCURDY ROAD, KELOWNA A1 23230 |
William Edward Mckechnie | director | 305 MARGARET AVENUE, KITCHENER A6 N2H 6S4 |
Allan Horst Spissinger | officer: CFO | 8131 198A STREET, LANGLEY A1 V2Y 1Y6 |
John Martin Docherty | director, 10 percent owner | 23 MIKELEN DRIVE, PORT PERRY A6 L9L 1V1 |
Baljinder Bhullar | director, officer: CFO | 604 - 700 WEST PENDER, VANCOUVER A1 V6C 1G8 |
Nicholas W Baxter | director | 220 SPRINGFIELD ROAD, ABERDEEN, ABERDEENSHIRE, SCOTLAND X0 AB15 6AU |
Dustin Arthur Elford | director | 888 - 609 WEST HASTINGS STREET, VANCOUVER A1 V6B 4W4 |
Thomas James Ihrke | officer: Sr. VP, Business Development | 38 KRIER LANE, MOUNT PLEASANT SC 29464 |
David Demartini | director, 10 percent owner | 11714 SPRIGGS WAY, HOUSTON TX 77024 |
Leonard Macmillan | director, officer: Vice President - Corp Develop | SUITE 302, 125A - 1030 DENMAN STREET, VANCOUVER A1 V6G 2M6 |
From GuruFocus
By ACCESSWIRE • 11-07-2024
By ACCESSWIRE • 10-17-2024
By ACCESSWIRE • 08-30-2024
By ACCESSWIRE • 09-03-2024
By ACCESSWIRE • 06-18-2024
By GuruFocus News • 12-03-2024
By ACCESSWIRE • 10-15-2024
By ACCESSWIRE • 08-27-2024
By ACCESSWIRE • 11-26-2024
By ACCESSWIRE • 08-19-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.